Cargando…

Is intrathecal anti-CD20 an option to target compartmentalized CNS inflammation in progressive MS?

Detalles Bibliográficos
Autor principal:	Weber, Martin S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360792/ https://www.ncbi.nlm.nih.gov/pubmed/25798446 http://dx.doi.org/10.1212/NXI.0000000000000084

Ejemplares similares

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity
por: Lehmann-Horn, Klaus, et al.
Publicado: (2014)

Compartmentalized intrathecal immunoglobulin synthesis during HIV infection — A model of chronic CNS inflammation?
por: Bonnan, Mickael, et al.
Publicado: (2015)

Intrathecal CD8(+)CD20(+) T Cells in Primary Progressive Multiple Sclerosis
por: von Essen, Marina Rode, et al.
Publicado: (2023)

Intrathecal Inflammation in Progressive Multiple Sclerosis
por: Monaco, Salvatore, et al.
Publicado: (2020)

Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease
por: Häusler, Darius, et al.
Publicado: (2018)

B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation
por: Michel, Laure, et al.
Publicado: (2015)

Safety of long-term intrathecal methotrexate in progressive forms of MS
por: Stark, James W., et al.
Publicado: (2019)

The Compartmentalization of Surgery
por: Kavic, Michael S.
Publicado: (1997)

B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets
por: Forsthuber, Thomas G., et al.
Publicado: (2018)

Inflammation in the CNS and PNS: From Molecular Basis to Therapy
por: Apolloni, Savina, et al.
Publicado: (2023)

Targeting Therapeutic Antibodies to the CNS: a Comparative Study of Intrathecal, Intravenous, and Subcutaneous Anti-Nogo A Antibody Treatment after Stroke in Rats
por: Wahl, Anna-Sophia, et al.
Publicado: (2020)

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
por: Shinoda, Koji, et al.
Publicado: (2023)

Intracellular compartmentation of cAMP promotes neuroprotection and regeneration of CNS neurons
por: Cameron, Evan G., et al.
Publicado: (2017)

Anti‐CD20 therapeutic options in immune‐mediated thrombotic thrombocytopenic purpura
por: Maitta, Robert W.
Publicado: (2022)

Differential compartmentalization of myeloid cell phenotypes and responses towards the CNS in Alzheimer’s disease
por: Fernández Zapata, Camila, et al.
Publicado: (2022)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Blunted Post-COVID-19 Humoral Immunity in Patients With CNS Demyelinating Disorders on Anti-CD20 Treatments
por: Money, Kelli M., et al.
Publicado: (2022)

Intravascular Lymphoma in the CNS: Options for Treatment
por: Nizamutdinov, Damir, et al.
Publicado: (2017)

Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates
por: Gray, Steven J., et al.
Publicado: (2013)

Applications of Theranostics for Detecting and Targeting CNS Injuries and Diseases
por: Sun, Yu-Yo, et al.
Publicado: (2022)

Potential Molecular Targets in the Treatment of Patients with CNS Tumors
por: Pan, Edward
Publicado: (2023)

Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension
por: Bergman, Joakim, et al.
Publicado: (2020)

Intrathecal Baclofen Therapy: Pros and Cons
por: Cho, Sung-Rae
Publicado: (2023)

Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab
por: Elhassadi, Ezzat, et al.
Publicado: (2018)

Determination of spinal tracer dispersion after intrathecal injection in a deformable CNS model
por: Ayansiji, Ayankola O., et al.
Publicado: (2023)

Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists
por: Kant, Sam, et al.
Publicado: (2021)

Change is Inevitable Progress is Optional
por: Peter, Joby
Publicado: (2021)

Phase separation may drive mitochondrial nucleoid compartmentation
por: Dalamaga, Maria, et al.
Publicado: (2022)

NCI-CONNECT rare CNS tumor initiative: current progress and anticipated future impact
por: Mansouri, Alireza, et al.
Publicado: (2020)

Potential for Targeting Myeloid Cells in Controlling CNS Inflammation
por: Ifergan, Igal, et al.
Publicado: (2020)

Pharmacological agonists for more-targeted CNS radio-pharmaceuticals
por: Zimmer, Luc
Publicado: (2016)

MS CD49d(+)CD154(+) Lymphocytes Reprogram Oligodendrocytes into Immune Reactive Cells Affecting CNS Regeneration
por: Piatek, Paweł, et al.
Publicado: (2019)

Myelinodegeneration vs. Neurodegeneration in MS Progressive Forms
por: Nataf, Serge
Publicado: (2023)

State of the globe: Antimicrobial Resistance: Need for De-compartmentalization of Action
por: Raina, Sunil Kumar
Publicado: (2019)

Principles of mathematical epidemiology and compartmental modelling application to COVID-19
por: Reyné, Bastien, et al.
Publicado: (2022)

Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis
por: Milstein, Joshua L., et al.
Publicado: (2019)

A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations
por: Yamamoto, Yumi, et al.
Publicado: (2016)

Can Systemic Anti-CD20 B Cell-Depleting Antibodies Eliminate Meningeal Follicles in Multiple Sclerosis?
por: Gupta, Sasha, et al.
Publicado: (2021)

Inflammation and Anti-Inflammatory Targets after Aneurysmal Subarachnoid Hemorrhage
por: Muhammad, Sajjad, et al.
Publicado: (2021)

Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells
por: Roscher, Mareike, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k9gaqh7a5b2shce5j7d71hc03a